{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:56:39Z","timestamp":1788386199184,"version":"build-2803163510"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,4,11]],"date-time":"2008-04-11T00:00:00Z","timestamp":1207872000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11102-008-0106-6","type":"journal-article","created":{"date-parts":[[2008,4,10]],"date-time":"2008-04-10T11:28:14Z","timestamp":1207826894000},"page":"209-218","source":"Crossref","is-referenced-by-count":141,"title":["Drugs and prolactin"],"prefix":"10.1007","volume":"11","author":[{"given":"Mark E.","family":"Molitch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,4,11]]},"reference":[{"key":"106_CR1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0889-8529(05)70203-6","volume":"30","author":"ME Molitch","year":"2001","unstructured":"Molitch ME (2001) Disorders of prolactin secretion. Endocrinol Metab Clin N Amer 30:585\u2013610. doi: 10.1016\/S0889-8529(05)70203-6","journal-title":"Endocrinol Metab Clin North Am"},{"key":"106_CR2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0889-8529(18)30442-0","volume":"17","author":"AI Green","year":"1988","unstructured":"Green AI, Brown WA (1988) Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 17:213\u2013223","journal-title":"Endocrinol Metab Clin North Am"},{"key":"106_CR3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/bmj.324.7332.250","volume":"324","author":"A Wieck","year":"2002","unstructured":"Wieck A, Haddad P (2002) Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324:250\u2013252. Medline. doi: 10.1136\/bmj.324.7332.250","journal-title":"BMJ"},{"issue":"Suppl 4","key":"106_CR4","first-page":"56","volume":"63","author":"A Maguire","year":"2002","unstructured":"Maguire A (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56\u201362. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0306-4530(80)90015-3","volume":"5","author":"RT Rubin","year":"1980","unstructured":"Rubin RT, Hays SE (1980) The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 5:121\u2013137. Medline. doi: 10.1016\/0306-4530(80)90015-3","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0306-4530(77)90007-5","volume":"2","author":"G Langer","year":"1977","unstructured":"Langer G, Sachar EJ (1977) Dopaminergic factors in human prolactin regulation: effects of neuroleptics and dopamine. Psychoneuroendocrinology 2:373\u2013378. Medline. doi: 10.1016\/0306-4530(77)90007-5","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1210\/jcem-45-5-996","volume":"45","author":"G Langer","year":"1977","unstructured":"Langer G, Sachar EJ, Halpern FS (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: neuroendocrine. J Clin Endocrinol Metab 45:996\u20131002. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR8","first-page":"693","volume":"91","author":"M Spitzer","year":"1998","unstructured":"Spitzer M, Siajjad R, Benjamin F (1998) Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 91:693\u2013695. Medline. doi: 10.1016\/S0029-7844(98)00066-0","journal-title":"Obstet Gynecol"},{"key":"106_CR9","first-page":"177","volume-title":"Hormones, behavior, and psychopathology","author":"HY Meltzer","year":"1976","unstructured":"Meltzer HY, Fang VS (1976) Serum prolactin levels in schizophrenia\u2014effect of antipsychotic drugs: a preliminary report. In: Sachar J (ed) Hormones, behavior, and psychopathology. Raven Press, New York, NY, pp 177\u2013190"},{"key":"106_CR10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2265.1976.tb01953.x","volume":"5","author":"JL Rivera De","year":"1976","unstructured":"De Rivera JL, Lal S, Ettigi P et\u00a0al (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273\u2013282. Medline","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2265.1998.00569.x","volume":"49","author":"A Pollock","year":"1998","unstructured":"Pollock A, McLaren EH (1998) Serum prolactin concentrations in patients taking neuroleptic drugs. Clin Endocrinol (Oxf) 49:513\u2013516. Medline. doi: 10.1046\/j.1365-2265.1998.00569.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00004714-200204000-00002","volume":"22","author":"S Smith","year":"2002","unstructured":"Smith S, Wheeler MJ, Murray R et\u00a0al (2002) The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 22:109\u2013114. Medline. doi: 10.1097\/00004714-200204000-00002","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/0006-3223(95)00589-7","volume":"39","author":"N Zelaschi","year":"1996","unstructured":"Zelaschi N, Delucchi GA, Rodriguez JL (1996) High prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 39:900\u2013901. doi: 10.1016\/0006-3223(95)00589-7","journal-title":"Biol Psychiatry"},{"key":"106_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, deCoster R et\u00a0al (1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57\u201361. Medline. doi: 10.1097\/00004714-199902000-00011","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0306-4530(02)00127-0","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H et\u00a0al (2003) Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 28:55\u201368. Medline. doi: 10.1016\/S0306-4530(02)00127-0","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","volume":"14","author":"M Hamner","year":"2002","unstructured":"Hamner M (2002) The effect of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 14:163\u2013173. Medline. doi: 10.1023\/A:1021138603935","journal-title":"Ann Clin Psychiatry"},{"key":"106_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H et\u00a0al (2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28:69\u201382. Medline. doi: 10.1016\/S0306-4530(02)00128-2","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4158\/EP.6.6.425","volume":"6","author":"AE Kearns","year":"2000","unstructured":"Kearns AE, Goff DC, Hayden DL et\u00a0al (2000) Risperidone-associated hyperprolactinemia. Endocr Pract 6:425\u2013429. Medline","journal-title":"Endocr Pract"},{"key":"106_CR19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","volume":"22","author":"SR David","year":"2000","unstructured":"David SR, Taylor CC, Kinon BJ et\u00a0al (2000) The effect of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085\u20131096. Medline. doi: 10.1016\/S0149-2918(00)80086-7","journal-title":"Clin Ther"},{"key":"106_CR20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","volume":"64","author":"D Becker","year":"2003","unstructured":"Becker D, Liver O, Mester R et\u00a0al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64:761\u2013766. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR21","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D et\u00a0al (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64:1362\u20131369. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","volume":"65","author":"J Volavka","year":"2004","unstructured":"Volavka J, Czobor P, Cooper TB et\u00a0al (2004) Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 65:57\u201361. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.jcp.0000203194.58087.9a","volume":"26","author":"L Holzer","year":"2006","unstructured":"Holzer L, Eap CB (2006) Risperidone-induced symptomatic hyperprolactinemia in adolescents. J Clin Psychopharmacol 26:167\u2013171. Medline. doi: 10.1097\/01.jcp.0000203194.58087.9a","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR24","first-page":"379","volume":"50","author":"AK Pandurangi","year":"1989","unstructured":"Pandurangi AK, Narasimhachari N, Blackard WG et\u00a0al (1989) Relation of serum molindone levels to serum prolactin levels and antipsychotic response. J Clin Psychiatry 50:379\u2013381. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","volume":"156","author":"AF Breier","year":"1999","unstructured":"Breier AF, Malhotra AK, Su T-P et\u00a0al (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294\u2013298. Medline","journal-title":"Am J Psychiatry"},{"key":"106_CR26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","volume":"159","author":"P Turrone","year":"2002","unstructured":"Turrone P, Kapur S, Seeman MV et\u00a0al (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133\u2013135. Medline. doi: 10.1176\/appi.ajp.159.1.133","journal-title":"Am J Psychiatry"},{"key":"106_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","volume":"26","author":"AM Crawford","year":"1997","unstructured":"Crawford AM, Beasley CM Jr, Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26:41\u201354. Medline. doi: 10.1016\/S0920-9964(97)00036-4","journal-title":"Schizophr Res"},{"key":"106_CR28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.v63n0506","volume":"63","author":"K-S Kim","year":"2002","unstructured":"Kim K-S, Pae C-U, Hae J-H et\u00a0al (2002) Effects of olanzapine on prolactin levels of female patients treated with schizophrenia treated with risperidone. J Clin Psychiatry 63:408\u2013413. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR29","first-page":"107","volume":"32","author":"MB Hamner","year":"1996","unstructured":"Hamner MB, Arvanitis LA, Miller BG et\u00a0al (1996) Plasma prolactin in schizophrenia subjects treated with SeroquelTM (ICI 204,636). Psychopharmacol Bull 32:107\u2013110. Medline","journal-title":"Psychopharmacol Bull"},{"key":"106_CR30","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0188-4409(02)00403-4","volume":"33","author":"M Atmaca","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E et\u00a0al (2002) Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 33:562\u2013565. Medline. doi: 10.1016\/S0188-4409(02)00403-4","journal-title":"Arch Med Res"},{"key":"106_CR31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","volume":"18","author":"DC Goff","year":"1998","unstructured":"Goff DC, Posever T, Herz L et\u00a0al (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296\u2013304. Medline. doi: 10.1097\/00004714-199808000-00009","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","volume":"166","author":"DE Casey","year":"2003","unstructured":"Casey DE, Carson WH, Saha AR, Aripiprazole Study Group et\u00a0al (2003) Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166:391\u2013399. Medline","journal-title":"Psychopharmacology (Berl)"},{"key":"106_CR33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","volume":"160","author":"PE Keck Jr","year":"2003","unstructured":"Keck PE Jr, Marcus R, Tourkodimitris S et\u00a0al (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160:1651\u20131568. Medline. doi: 10.1176\/appi.ajp.160.9.1651","journal-title":"Am J Psychiatry"},{"key":"106_CR34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","volume":"47","author":"P Seeman","year":"2002","unstructured":"Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27\u201338. Medline","journal-title":"Can J Psychiatry"},{"key":"106_CR35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","volume":"65","author":"M Misra","year":"2004","unstructured":"Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65:1607\u20131618. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR36","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","volume":"60","author":"A Gr\u00fcnder. Carlsson","year":"2003","unstructured":"Gr\u00fcnder. Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications. Occupancy is not just antagonism. Arch Gen Psychiatry 60:974\u2013977. Medline. doi: 10.1001\/archpsyc.60.10.974","journal-title":"Arch Gen Psychiatry"},{"key":"106_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","volume":"28","author":"AJ Cutler","year":"2003","unstructured":"Cutler AJ (2003) Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28:69\u201382. Medline. doi: 10.1016\/S0306-4530(02)00113-0","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0306-4530(02)00130-0","volume":"28","author":"H Knegtering","year":"2003","unstructured":"Knegtering H, van der Mooler AEGM, Castelein S et\u00a0al (2003) What are the effects of antipsychotics on sexual dysfunction and endocrine functioning. Psychoneuroendocrinology 28:109\u2013123. Medline. doi: 10.1016\/S0306-4530(02)00130-0","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1043-6618(03)00174-9","volume":"48","author":"S Brunelleschi","year":"2003","unstructured":"Brunelleschi S, Zeppegno P, Risso F et\u00a0al (2003) Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol Res 48:405\u2013409. Medline. doi: 10.1016\/S1043-6618(03)00174-9","journal-title":"Pharmacol Res"},{"key":"106_CR40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","volume":"24","author":"R Knegtering","year":"2004","unstructured":"Knegtering R, Castelein S, Bous H et\u00a0al (2004) A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 24:56\u201361. Medline. doi: 10.1097\/01.jcp.0000106220.36344.04","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0015-0282(16)60365-5","volume":"50","author":"K Ataya","year":"1988","unstructured":"Ataya K, Abbasi A, Mercado A et\u00a0al (1988) Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876\u2013881. Medline","journal-title":"Fertil Steril"},{"key":"106_CR42","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","volume":"161","author":"F Dunbar","year":"2004","unstructured":"Dunbar F, Kusumakar V, Daneman D et\u00a0al (2004) Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161:918\u2013920. Medline. doi: 10.1176\/appi.ajp.161.5.918","journal-title":"Am J Psychiatry"},{"key":"106_CR43","first-page":"303","volume-title":"Typical and atypical antidepressants: clinical practice","author":"HY Meltzer","year":"1982","unstructured":"Meltzer HY, Fang VS, Tricou BJ et\u00a0al (1982) Effect of antidepressants on neuroendocrine axis in humans. In: Costa E, Racagni G (eds) Typical and atypical antidepressants: clinical practice. Raven Press, New York, NY, pp 303\u2013316"},{"key":"106_CR44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archpsyc.1989.01810070051009","volume":"46","author":"LH Price","year":"1989","unstructured":"Price LH, Charney DS, Delgado PL et\u00a0al (1989) Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action. Arch Gen Psychiatry 46:625\u2013631. Medline","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 4","key":"106_CR45","first-page":"166","volume":"53","author":"RB Jones","year":"1977","unstructured":"Jones RB, Luscombe DK, Groom GV (1977) Plasma prolactin concentrations in normal subjects and depressive patients following oral clomipramine. Postgrad Med J 53(Suppl 4):166\u201371","journal-title":"Postgrad Med J"},{"key":"106_CR46","first-page":"851","volume":"11","author":"PA Marken","year":"1992","unstructured":"Marken PA, Haykal RF, Fisher JN (1992) Management of psychotropic-induced hyperprolactinemia. Clin Pharm 11:851\u2013856. Medline","journal-title":"Clin Pharm"},{"key":"106_CR47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(77)90956-4","volume":"2","author":"SL Slater","year":"1977","unstructured":"Slater SL, Lipper S, Shiling DJ et\u00a0al (1977) Elevation of plasma-prolactin by monoamine-oxidase inhibitors. Lancet 2:275\u2013276. Medline. doi: 10.1016\/S0140-6736(77)90956-4","journal-title":"Lancet"},{"key":"106_CR48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/0024-3205(85)90515-6","volume":"37","author":"LH Price","year":"1985","unstructured":"Price LH, Charney DS, Heninger GR (1985) Effects of tranylcypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. Life Sci 37:809\u2013818. Medline. doi: 10.1016\/0024-3205(85)90515-6","journal-title":"Life Sci"},{"key":"106_CR49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00012995-199806000-00001","volume":"190","author":"MA Cohen","year":"1998","unstructured":"Cohen MA, Davies PH (1998) Drug therapy and hyperprolactinaemia. Adverse Drug React Bull 190:723\u2013726","journal-title":"Adverse Drug React Bull"},{"key":"106_CR50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9378(91)90645-8","volume":"164","author":"RJ Urban","year":"1991","unstructured":"Urban RJ, Veldhuis JD (1991) A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Am J Obstet Gynecol 164:147\u2013152. Medline","journal-title":"Am J Obstet Gynecol"},{"key":"106_CR51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/026988119701100410","volume":"11","author":"PJ Cowen","year":"1997","unstructured":"Cowen PJ, Sargent PA (1997) Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 11:345\u2013348. Medline","journal-title":"J Psychopharmacol"},{"key":"106_CR52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0165-0327(97)00086-4","volume":"46","author":"JD Amsterdam","year":"1997","unstructured":"Amsterdam JD, Garcia-Espa\u00f1a F, Goodman D et\u00a0al (1997) Breast enlargement during chronic antidepressant therapy. J Affect Dis 46:151\u2013156. Medline. doi: 10.1016\/S0165-0327(97)00086-4","journal-title":"J Affect Dis"},{"key":"106_CR53","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0278-5846(02)00259-2","volume":"26","author":"D M\u00fcck-\u0160eler","year":"2002","unstructured":"M\u00fcck-\u0160eler D, Pivac N, \u0160agud M et\u00a0al (2002) The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression. Prog Neuropsychopharmacol Biol Psychiatry 26:1235\u20131243. Medline. doi: 10.1016\/S0278-5846(02)00259-2","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"106_CR54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00002826-199710000-00006","volume":"20","author":"K Laine","year":"1997","unstructured":"Laine K, Anttila M, Heinonen E et\u00a0al (1997) Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 20:419\u2013433. Medline. doi: 10.1097\/00002826-199710000-00006","journal-title":"Clin Neuropharmacol"},{"key":"106_CR55","first-page":"332","volume":"22","author":"J Shlik","year":"1997","unstructured":"Shlik J, Aluoja A, Vasar V et\u00a0al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332\u2013340. Medline","journal-title":"J Psychiatry Neurosci"},{"key":"106_CR56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002130050610","volume":"137","author":"C Gordon","year":"1998","unstructured":"Gordon C, Whale R, Cowen PJ (1998) Sertraline treatment does not increase plasma prolactin levels in healthy subjects. Psychopharmacology (Berl) 137:201\u2013202. Medline. doi: 10.1007\/s002130050610","journal-title":"Psychopharmacology (Berl)"},{"key":"106_CR57","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000054954","volume":"45","author":"M \u0160agud","year":"2002","unstructured":"\u0160agud M, Pivac N, M\u00fcck-\u0160eler D et\u00a0al (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45:139\u2013143. Medline. doi: 10.1159\/000054954","journal-title":"Neuropsychobiology"},{"key":"106_CR58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004714-199708000-00009","volume":"17","author":"O Spigset","year":"1997","unstructured":"Spigset O, Mj\u00f6ndal T (1997) The effect of fluvoxamine on serum prolactin, serum sodium concentrations: relation to platelet 5-HT2A receptor status. J Clin Psychopharmacol 17:292\u2013297. Medline. doi: 10.1097\/00004714-199708000-00009","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00004583-199207000-00032","volume":"31","author":"I Iancu","year":"1992","unstructured":"Iancu I, Ratzoni G, Weitzman A et\u00a0al (1992) More fluoxetine experience. J Am Acad Child Adolesc Psychiatry 31:755\u2013756. Medline. doi: 10.1097\/00004583-199207000-00032","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"106_CR60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0025-6196(11)63132-7","volume":"76","author":"MC Peterson","year":"2001","unstructured":"Peterson MC (2001) Reversible galactorrhea and prolactin elevation related to fluoxetine use. Mayo Clin Proc 76:215\u2013216. Medline","journal-title":"Mayo Clin Proc"},{"key":"106_CR61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.npp.1300412","volume":"29","author":"ABF Emiliano","year":"2004","unstructured":"Emiliano ABF, Fudge JL (2004) From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacol 29:833\u2013846. doi: 10.1038\/sj.npp.1300412","journal-title":"Neuropsychopharmacol"},{"key":"106_CR62","first-page":"268","volume":"14","author":"AE Walsh","year":"1994","unstructured":"Walsh AE, Cowen PJ (1994) Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 14:268\u2013273. Medline","journal-title":"J Clin Psychopharmacol"},{"key":"106_CR63","first-page":"209","volume":"44","author":"PD Whiteman","year":"1983","unstructured":"Whiteman PD, Peck AW, Fowle AS et\u00a0al (1983) Failure of bupropion to affect prolactin or growth hormone in man. J Clin Psychiatry 44:209\u2013210. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00002826-198506000-00006","volume":"8","author":"U Bonuccelli","year":"1985","unstructured":"Bonuccelli U, Murialdo G, Martino E et\u00a0al (1985) Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects. Clin Neuropharmacol 8:165\u2013174. Medline. doi: 10.1097\/00002826-198506000-00006","journal-title":"Clin Neuropharmacol"},{"key":"106_CR65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0165-1781(88)90059-5","volume":"24","author":"LH Price","year":"1988","unstructured":"Price LH, Charney DS, Heninger GR (1988) Effects of trazodone treatment on serotonergic function in depressed patients. Psychiatry Res 24:165\u2013175. Medline. doi: 10.1016\/0165-1781(88)90059-5","journal-title":"Psychiatry Res"},{"key":"106_CR66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-199506000-00009","volume":"10","author":"K Otani","year":"1995","unstructured":"Otani K, Yasui N, Kaneko S et\u00a0al (1995) Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol 10:115\u2013117. Medline. doi: 10.1097\/00004850-199506000-00009","journal-title":"Int Clin Psychopharmacol"},{"key":"106_CR67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0278-5846(00)00165-2","volume":"25","author":"M Bat\u00fcrk","year":"2001","unstructured":"Bat\u00fcrk M, Karaaslan F, E\u015fel E et\u00a0al (2001) Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 25:315\u2013322. Medline. doi: 10.1016\/S0278-5846(00)00165-2","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"106_CR68","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1210\/jcem-41-4-797","volume":"41","author":"G Tolis","year":"1975","unstructured":"Tolis G, Hickey J, Guyda H (1975) Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 41:797\u2013800. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR69","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0306-4530(84)90050-7","volume":"9","author":"AP Zis","year":"1984","unstructured":"Zis AP, Haskett RF, Albala AA et\u00a0al (1984) Morphine inhibits cortisol and stimulates prolactin secretion in man. Psychoneuroendocrinology 9:423\u2013427.Medline. doi: 10.1016\/0306-4530(84)90050-7","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2265.1979.tb02115.x","volume":"10","author":"V Chan","year":"1979","unstructured":"Chan V, Wang C, Yeung TT (1979) Effects of heroin addiction on thyrotrophin, thyroid hormones and prolactin secretion in men. Clin Endocrinol (Oxf) 10:557\u2013565. Medline","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR71","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0306-4530(79)90028-3","volume":"4","author":"MA Afrasiabi","year":"1979","unstructured":"Afrasiabi MA, Flomm M, Friedlander H et\u00a0al (1979) Endocrine studies in heroin addicts. Psychoneuroendocrinology 4:145\u2013153. Medline. doi: 10.1016\/0306-4530(79)90028-3","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.103.050682","volume":"306","author":"G Bart","year":"2003","unstructured":"Bart G, Borg L, Schluger JH et\u00a0al (2003) Suppressed prolactin response to dynorphin A1\u201313 in methadone-maintained versus control subjects. J Pharmacol Exp Ther 306:581\u2013587. Medline. doi: 10.1124\/jpet.103.050682","journal-title":"J Pharmacol Exp Ther"},{"key":"106_CR73","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1210\/endo-117-3-1096","volume":"117","author":"AE Panerai","year":"1985","unstructured":"Panerai AE, Petraglia F, Sacerdote P et\u00a0al (1985) Mainly \u03bc-opiate receptors are involved in luteinizing hormone and prolactin secretion. Endocrinology 117:1096\u20131099. Medline","journal-title":"Endocrinology"},{"key":"106_CR74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/jcem-62-1-181","volume":"62","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Braun S, Mann K (1986) Anterior pituitary hormone responses to a k-opioid agonist in man. J Clin Endocrinol Metab 62:181\u2013185. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000124712","volume":"45","author":"CA Leadem","year":"1987","unstructured":"Leadem CA, Yagenova SV (1987) Effects of specific activation of mu-, delta- and kappa-opioid receptors on the secretion of luteinizing hormone and prolactin in the ovariectomized rat. Neuroendocrinology 45:109\u2013117. Medline","journal-title":"Neuroendocrinology"},{"key":"106_CR76","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/0024-3205(79)90534-4","volume":"24","author":"DA Vugt Van","year":"1979","unstructured":"Van Vugt DA, Bruni JF, Sylvester PW et\u00a0al (1979) Interaction between opiates and hypothalamic dopamine on prolactin release. Life Sci 24:2361\u20132368. MEdline. doi: 10.1016\/0024-3205(79)90534-4","journal-title":"Life Sci"},{"key":"106_CR77","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1210\/endo-106-1-76","volume":"106","author":"GR Loon Van","year":"1980","unstructured":"Van Loon GR, Ho D, Kim C (1980) \u00df-endorphin-induced decrease in hypothalamic dopamine turnover. Endocrinology 106:76\u201380. Medline","journal-title":"Endocrinology"},{"key":"106_CR78","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/0024-3205(79)90411-9","volume":"25","author":"GA Gudelsky","year":"1979","unstructured":"Gudelsky GA, Porter JC (1979) Morphine- and opioid peptide-induced inhibition of the release of dopamine from tuberoinfundibular neurons. Life Sci 25:1697\u20131702. Medline. doi: 10.1016\/0024-3205(79)90411-9","journal-title":"Life Sci"},{"key":"106_CR79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-1781(90)90069-H","volume":"33","author":"MA Lee","year":"1990","unstructured":"Lee MA, Bowers MM, Nash JF et\u00a0al (1990) Neuroendocrine measures of dopaminergic function in chronic cocaine users. Psychiatry Res 33:151\u2013159. Medline. doi: 10.1016\/0165-1781(90)90069-H","journal-title":"Psychiatry Res"},{"key":"106_CR80","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1210\/jcem-69-6-1256","volume":"69","author":"JH Mendelson","year":"1989","unstructured":"Mendelson JH, Mello NK, Teoh SK et\u00a0al (1989) Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones. J Clin Endocrinol Metab 69:1256\u20131260. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR81","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-2007-1013583","volume":"17","author":"E Maestri","year":"1985","unstructured":"Maestri E, Camellini L, Rossi G et\u00a0al (1985) Effects of five days verapamil administration on serum GH and PRL levels. Horm Metab Res 17:482. Medline","journal-title":"Horm Metab Res"},{"key":"106_CR82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00000441-199211000-00004","volume":"304","author":"TJ Kamal","year":"1992","unstructured":"Kamal TJ, Molitch ME (1992) Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-DOPA and bromocriptine. Am J Med Sci 304:289\u2013293. Medline. doi: 10.1097\/00000441-199211000-00004","journal-title":"Am J Med Sci"},{"key":"106_CR83","doi-asserted-by":"crossref","unstructured":"Kelley SR, Kamal TJ, Molitch ME (1996) Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia. Am J Physiol 270 (Endocrinol Metab 33):E96\u2013E100","DOI":"10.1152\/ajpendo.1996.270.1.E96"},{"key":"106_CR84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.7326\/0003-4819-95-1-66","volume":"95","author":"LE Gluskin","year":"1981","unstructured":"Gluskin LE, Strasberg B, Shah JH (1981) Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med 95:66\u201367. Medline","journal-title":"Ann Intern Med"},{"key":"106_CR85","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/0002-9149(83)90336-3","volume":"51","author":"EL Fearrington","year":"1983","unstructured":"Fearrington EL, Rand CH, Rose JD (1983) Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 51:1446. Medline. doi: 10.1016\/0002-9149(83)90336-3","journal-title":"Am J Cardiol"},{"key":"106_CR86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2265.1996.00859.x","volume":"45","author":"JH Romeo","year":"1996","unstructured":"Romeo JH, Dombrowski R, Kwak YS et\u00a0al (1996) Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 45:571\u2013575. Medline. doi: 10.1046\/j.1365-2265.1996.00859.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR87","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.1.6019.1186","volume":"1","author":"J Steiner","year":"1976","unstructured":"Steiner J, Cassar J, Mashiter K et\u00a0al (1976) Effect of methyldopa on prolactin and growth hormone. BMJ 1:1186\u20131188. Medline","journal-title":"BMJ"},{"key":"106_CR88","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.1976.03260470034022","volume":"235","author":"PA Lee","year":"1976","unstructured":"Lee PA, Kelly MR, Wallin JD (1976) Increased prolactin levels during reserpine treatment of hypertensive patients. JAMA 235:2316\u20132317. Medline. doi: 10.1001\/jama.235.21.2316","journal-title":"JAMA"},{"key":"106_CR89","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1210\/jcem-71-1-256","volume":"71","author":"LM Winer","year":"1990","unstructured":"Winer LM, Molteni A, Molitch ME (1990) Effect of angiotensin\u2014converting enzyme inhibition on pituitary hormone response to insulin\u2014induced hypoglycemia in humans. J Clin Endocrinol Metab 71:256\u2013259. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR90","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2265.1982.tb03178.x","volume":"16","author":"C Barbieri","year":"1982","unstructured":"Barbieri C, Larovere MT, Mariotti G et\u00a0al (1982) Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Clin Endocrinol (Oxf) 16:615\u2013619. Medline","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR91","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1210\/jcem-47-3-675","volume":"47","author":"T Aono","year":"1978","unstructured":"Aono T, Shioji T, Kinugasa T et\u00a0al (1978) Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab 47:675\u2013680. Medline","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR92","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000179051","volume":"11","author":"EI Tamagna","year":"1979","unstructured":"Tamagna EI, Lane WS, Hershman JM et\u00a0al (1979) Effect of chronic metoclopramide therapy on serum pituitary hormone concentrations. Horm Res 11:161\u2013169. Medline","journal-title":"Horm Res"},{"key":"106_CR93","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1507\/endocrj1954.27.521","volume":"27","author":"T Fujino","year":"1980","unstructured":"Fujino T, Kato H, Yamashita S et\u00a0al (1980) Effects of domperidone on serum prolactin levels in human beings. Endocrinol Jpn 27:521\u2013525","journal-title":"Endocrinol Jpn"},{"key":"106_CR94","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(77)91358-7","volume":"1","author":"GF Delle Fave","year":"1977","unstructured":"Delle Fave GF, Tamburrano G, de Magistris L et\u00a0al (1977) Gynaecomastia with cimetidine. Lancet 1:1319. Medline. doi: 10.1016\/S0140-6736(77)91358-7","journal-title":"Lancet"},{"key":"106_CR95","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(77)90260-4","volume":"2","author":"M Petrillo","year":"1977","unstructured":"Petrillo M, Parada A, Porro GB et\u00a0al (1977) Plasma prolactin and cimetidine. Lancet 2:761. Medline. doi: 10.1016\/S0140-6736(77)90260-4","journal-title":"Lancet"},{"key":"106_CR96","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(78)90229-5","volume":"1","author":"AM Spiegel","year":"1978","unstructured":"Spiegel AM, Lopatin R, Peikin S et\u00a0al (1978) Serum prolactin in patients receiving chronic oral cimetidine. Lancet 1:881. MEdline. doi: 10.1016\/S0140-6736(78)90229-5","journal-title":"Lancet"},{"key":"106_CR97","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.1.6110.409","volume":"1","author":"SK Majumdar","year":"1978","unstructured":"Majumdar SK, Thomson AD, Shaw GK (1978) Cimetidine and serum prolactin. BMJ 1:409\u2013410. Medline","journal-title":"BMJ"},{"key":"106_CR98","first-page":"129","volume":"5","author":"C Scarpignato","year":"1979","unstructured":"Scarpignato C, Bertaccini G (1979) Cimetidine and endocrine secretions: a short review. Drugs Exp Clin Res 5:129\u2013140","journal-title":"Drugs Exp Clin Res"},{"key":"106_CR99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(83)90022-3","volume":"2","author":"L Lombardo","year":"1983","unstructured":"Lombardo L (1983) More about ranitidine and hyperprolactinaemia. Lancet 2:42\u201343. Medline. doi: 10.1016\/S0140-6736(83)90022-3","journal-title":"Lancet"},{"key":"106_CR100","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF01313585","volume":"26","author":"HE Carlson","year":"1981","unstructured":"Carlson HE, Ippoliti AF, Swerdloff RS (1981) Endocrine effects of acute and chronic cimetidine administration. Dig Dis Sci 26:428\u2013432. Medline. doi: 10.1007\/BF01313585","journal-title":"Dig Dis Sci"},{"key":"106_CR101","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/0140-6736(93)92729-D","volume":"342","author":"G Delpre","year":"1993","unstructured":"Delpre G, Lapidot M, Lipchitz A et\u00a0al (1993) Hyperprolactinaemia during famotidine therapy. Lancet 342:868. Medline. doi: 10.1016\/0140-6736(93)92729-D","journal-title":"Lancet"},{"key":"106_CR102","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0140-6736(00)02697-0","volume":"356","author":"J Hutchinson","year":"2000","unstructured":"Hutchinson J, Murphy M, Harries R et\u00a0al (2000) Galactorrhea and hyperprolactinemia associated with protease inhibitors. Lancet 356:1003\u20131004. Medline. doi: 10.1016\/S0140-6736(00)02697-0","journal-title":"Lancet"},{"key":"106_CR103","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(05)71275-7","volume":"357","author":"A Montero","year":"2001","unstructured":"Montero A, Bottasso OA, Luraghi MR et\u00a0al (2001) Galactorrhoea, hyperprolactinaemia, and protease inhibitors. Lancet 357:473\u2013474. MEdline. doi: 10.1016\/S0140-6736(05)71275-7","journal-title":"Lancet"},{"key":"106_CR104","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ecl.2005.09.011","volume":"34","author":"ME Molitch","year":"2006","unstructured":"Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 34:99\u2013116. doi: 10.1016\/j.ecl.2005.09.011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"106_CR105","first-page":"8","volume":"55","author":"JV Reyniak","year":"1980","unstructured":"Reyniak JV, Wenof M, Aubert JM et\u00a0al (1980) Incidence of hyperprolactinemia during oral contraceptive therapy. Obstet Gynecol 55:8\u201311. Medline","journal-title":"Obstet Gynecol"},{"key":"106_CR106","first-page":"506","volume":"65","author":"AA Luciano","year":"1985","unstructured":"Luciano AA, Sherman BM, Chapler FK et\u00a0al (1985) Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 65:506. Medline","journal-title":"Obstet Gynecol"},{"key":"106_CR107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0010-7824(76)90076-7","volume":"13","author":"S Abu-Fadil","year":"1976","unstructured":"Abu-Fadil S, DeVane G, Siler TM et\u00a0al (1976) Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception 13:79\u201395. Medline. doi: 10.1016\/0010-7824(76)90076-7","journal-title":"Contraception"},{"key":"106_CR108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2265.1984.tb03438.x","volume":"20","author":"JRE Davis","year":"1984","unstructured":"Davis JRE, Selby C, Jeffcoate WJ (1984) Oral contraceptive agents do not affect serum prolactin in normal women. Clin Endocrinol (Oxf) 20:427\u2013434. Medline","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2265.1986.tb00754.x","volume":"24","author":"PLH Hwang","year":"1986","unstructured":"Hwang PLH, Ng CSA, Cheong ST (1986) Effect of oral contraceptives on serum prolactin: a longitudinal study in 126 normal premenopausal women. Clin Endocrinol (Oxf) 24:127\u2013133. Medline","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0015-0282(16)59165-1","volume":"47","author":"JB Josimovich","year":"1987","unstructured":"Josimovich JB, Lavenhar MA, Devanesan MM et\u00a0al (1987) Heterogeneous distribution of serum prolactin values in apparently healthy young women, and the effects of oral contraceptive medication. Fertil Steril 47:785\u2013791. Medline","journal-title":"Fertil Steril"},{"key":"106_CR111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-7824(91)90115-V","volume":"44","author":"V DeLeo","year":"1991","unstructured":"DeLeo V, Lanzetta D, Vanni AL et\u00a0al (1991) Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception 44:155\u2013161. Medline. doi: 10.1016\/0010-7824(91)90115-V","journal-title":"Contraception"},{"key":"106_CR112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-5122(82)90015-9","volume":"4","author":"A Grasso","year":"1982","unstructured":"Grasso A, Baraghini F, Barbieri C et\u00a0al (1982) Endocrinological features and endometrial morphology in climacteric women receiving hormone replacement therapy. Maturitas 4:19\u201326. Medline. doi: 10.1016\/0378-5122(82)90015-9","journal-title":"Maturitas"},{"key":"106_CR113","first-page":"202","volume":"39","author":"G Perrone","year":"1994","unstructured":"Perrone G, Falaschi P, Capri O et\u00a0al (1994) Hormonal and metabolic effects of transdermal estradiol\/progestagen administration in postmenopausal women. Int J Fertil Menopausal Stud 39:202\u2013207. Medline","journal-title":"Int J Fertil Menopausal Stud"},{"key":"106_CR114","first-page":"556","volume":"40","author":"C Castel-Branco","year":"1995","unstructured":"Castel-Branco C, Mart\u00ednez de Osaba MJ, Fortuny A et\u00a0al (1995) Circulating hormone levels in menopausal women receiving different hormone replacement therapy regimens. A comparison J Reprod Med 40:556\u2013560. Medline","journal-title":"A comparison J Reprod Med"},{"key":"106_CR115","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000291502","volume":"44","author":"D Foth","year":"1997","unstructured":"Foth D, R\u00f6mer T (1997) Prolactin serum levels in postmenopausal women receiving long-term hormone replacement therapy. Gynecol Obstet Invest 44:124\u2013126. Medline","journal-title":"Gynecol Obstet Invest"},{"key":"106_CR116","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2265.1999.00857.x","volume":"51","author":"W Schlegel","year":"1999","unstructured":"Schlegel W, Petersdorf LI, Juner R et\u00a0al (1999) The effects of six months of treatment with a low-dose of conjugated estrogens in menopausal women. Clin Endocrinol (Oxf) 51:643\u2013651. Medline. doi: 10.1046\/j.1365-2265.1999.00857.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"106_CR117","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/1097-0142(19880601)61:11<2187::AID-CNCR2820611109>3.0.CO;2-7","volume":"61","author":"H Matzkin","year":"1988","unstructured":"Matzkin H, Haver I, Lewyshon O et\u00a0al (1988) The role of increased prolactin levels under GnRH analogue treatment in advanced prostate carcinoma. Cancer 61:2187\u20132191. Medline. doi: 10.1002\/1097-0142(19880601)61:11<2187::AID-CNCR2820611109>3.0.CO;2-7","journal-title":"Cancer"},{"key":"106_CR118","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000473571","volume":"19","author":"YI Siegel","year":"1991","unstructured":"Siegel YI, Korczak D, Lindner A (1991) Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 19:16\u201318. Medline","journal-title":"Eur Urol"},{"key":"106_CR119","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0015-0282(16)57724-3","volume":"64","author":"A Kauschansky","year":"1995","unstructured":"Kauschansky A, Nussinovitch M, Frydman M et\u00a0al (1995) Hyperprolactinemia after treatment of long-acting gonadotropin-releasing analogue Decapetyl in girls with central precocious puberty. Fertil Steril 64:285\u2013287. Medline","journal-title":"Fertil Steril"},{"key":"106_CR120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.fertnstert.2005.03.041","volume":"84","author":"F Massart","year":"2005","unstructured":"Massart F, Parrino R, Placidi G et\u00a0al (2005) Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children. Fertil Steril 84:719\u2013724. Medline. doi: 10.1016\/j.fertnstert.2005.03.041","journal-title":"Fertil Steril"},{"key":"106_CR121","first-page":"709","volume-title":"Prolactin Basic and Clinical Correlates","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Reichlin S (1985) Hypothalamic hyperprolactinemia: neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk. In: MacLeod RM, Thorner MO, Scapagnini U (eds) Prolactin basic and clinical correlates. Liviana Press, Padova, Italy, pp 709\u2013719"},{"key":"106_CR122","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9343(87)90373-1","volume":"82","author":"JS Bevan","year":"1987","unstructured":"Bevan JS, Burke CW, Esiri MM et\u00a0al (1987) Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement. Am J Med 82:29\u201332. Medline. doi: 10.1016\/0002-9343(87)90373-1","journal-title":"Am J Med"},{"key":"106_CR123","first-page":"3507","volume":"80","author":"BM Arafah","year":"1995","unstructured":"Arafah BM, Neki KE, Gold RS et\u00a0al (1995) Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas. J Clin Endocrinol Metab 80:3507\u20133512. Medline. doi: 10.1210\/jc.80.12.3507","journal-title":"J Clin Endocrinol Metab"},{"key":"106_CR124","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0889-8529(05)70057-8","volume":"28","author":"MJ Naidich","year":"1999","unstructured":"Naidich MJ, Russell EJ (1999) Current approaches to imaging of the sellar region and pituitary. Endocrinol Metab Clin North Am 28:45\u201379. doi: 10.1016\/S0889-8529(05)70057-8","journal-title":"Endocrinol Metab Clin N Amer"},{"key":"106_CR125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/appi.neuropsych.15.3.375","volume":"15","author":"H Takahashi","year":"2003","unstructured":"Takahashi H, Higuchi H, Kamata M et\u00a0al (2003) Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsyc Clin Neurosci 15:375\u2013377","journal-title":"J Neuropsyc Clin Neurosci"},{"key":"106_CR126","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s100720200047","volume":"23","author":"R Keller","year":"2002","unstructured":"Keller R, Mongini F (2002) Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 23:233\u2013235. Medline. doi: 10.1007\/s100720200047","journal-title":"Neurol Sci"},{"key":"106_CR127","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.pnpbp.2006.02.001","volume":"30","author":"B-H Lee","year":"2006","unstructured":"Lee B-H, Kim Y-K, Park S-H (2006) Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30:714\u2013717. doi: 10.1016\/j.pnpbp.2006.02.001","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"106_CR128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","volume":"31","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Ahl J, Liu-Seifert H et\u00a0al (2006) Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31:577\u2013588. Medline. doi: 10.1016\/j.psyneuen.2005.12.006","journal-title":"Psychoneuroendocrinology"},{"key":"106_CR129","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","volume":"61","author":"A Tschoner","year":"2007","unstructured":"Tschoner A, Engl J, Laimer M et\u00a0al (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61:1356\u20131370. Medline. doi: 10.1111\/j.1742-1241.2007.01416.x","journal-title":"Int J Clin Pract"},{"key":"106_CR130","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.126.3.285","volume":"126","author":"P Beumont","year":"1975","unstructured":"Beumont P, Bruwer J, Pimstone B, Vinik A, Utian W (1975) Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br J Psychiatry 126:285\u2013288. Medline","journal-title":"Br J Psychiatry"},{"key":"106_CR131","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000118184","volume":"13","author":"JB Cohen","year":"1985","unstructured":"Cohen JB, Brust J, DiSerio F, Singer J (1985) Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 13:173\u2013179. Medline","journal-title":"Neuropsychobiology"},{"key":"106_CR132","first-page":"737","volume":"37","author":"J Smith","year":"1992","unstructured":"Smith J (1992) Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine? J Reprod Med 37:737\u2013740. Medline","journal-title":"J Reprod Med"},{"key":"106_CR133","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF03345068","volume":"23","author":"SR Tollin","year":"2000","unstructured":"Tollin SR (2000) Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23:765\u2013770. Medline","journal-title":"J Endocrinol Invest"},{"key":"106_CR134","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4088\/JCP.v65n0207","volume":"65","author":"R Cavallaro","year":"2004","unstructured":"Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E (2004) Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 65:187\u2013190. Medline","journal-title":"J Clin Psychiatry"},{"key":"106_CR135","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/104454601317261618","volume":"11","author":"L Glassner-Cohen","year":"2001","unstructured":"Glassner-Cohen L, Biederman J (2001) Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adol Psychopharmacol 11:435\u2013440. doi: 10.1089\/104454601317261618","journal-title":"J Child Adol Psychopharmacol"},{"key":"106_CR136","first-page":"252","volume":"43","author":"PE Frye","year":"1982","unstructured":"Frye PE, Pariser SF, Kim MH et\u00a0al (1982) Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J Clin Psychiatry 43:252\u2013253. Medline","journal-title":"J Clin Psychiatry"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-008-0106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-008-0106-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-008-0106-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:47:06Z","timestamp":1684324026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-008-0106-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,11]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["106"],"URL":"https:\/\/doi.org\/10.1007\/s11102-008-0106-6","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,11]]}}}